Effective treatment for relapsed/refractory (R/R) mantle cell lymphoma (MCL) post ibrutinib therapy represents an unmet clinical need. Simon Rule, MD, Plymouth University, Plymouth, UK, discusses the use of R-BAC (rituximab, bendamustine and cytarabine) in the post-Bruton’s tyrosine kinase inhibitor (BTKi) setting. Results from the study support R-BAC being considered a new standard of care option for R/R MCL post ibrutinib. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
